Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics, Inc. (Nasdaq: GANX) announced the appointment of C. Evan Ballantyne as Chief Financial Officer, effective immediately, succeeding Salvatore Calabrese. Ballantyne brings over 20 years of experience in healthcare finance, having previously served as CFO at OncXerna Therapeutics and Orchestra Biomed. He has a track record of raising significant capital, including $30 million at OncXerna and $57 million at Orchestra. Under his guidance, Gain Therapeutics aims to transition to a clinical-stage company with its lead program targeting GBA1 Parkinson's disease entering the clinic this year. The company has also granted Ballantyne equity awards as an inducement for joining. Gain Therapeutics focuses on allosteric small molecule therapies with a pipeline targeting neurodegenerative diseases and metabolic disorders.

Gain Therapeutics, Inc. (GANX) announced promising pre-clinical data supporting the potential therapeutic effects of its allosteric small molecule therapies for Alzheimer’s disease. Presented at the 2023 AD/PD Conference, the data shows that their compounds significantly improve neuronal survival and reduce toxicity from Amyloid Beta and Tau proteins in cell models. The STAR compounds exhibit disease-modifying properties, showcasing their potential to avert neurodegeneration associated with Alzheimer’s disease. Gain Therapeutics aims to advance research in allosteric regulators, with further updates expected throughout the year.

Gain Therapeutics (NASDAQ: GANX) reported significant progress in its pipeline and financial results for the year ending December 31, 2022. The company plans to submit a dossier for a Phase 1 clinical trial of GT-02287 for GBA1 Parkinson’s Disease by mid-2023. As of December 31, 2022, Gain had $22.1 million in cash and equivalents and received a €1.2 million non-dilutive grant for research in Alpha-1 Antitrypsin Deficiency. However, the net loss increased to $17.59 million compared to $13.89 million in 2021, primarily due to rising R&D and G&A expenses. The company expects existing funds to sustain operations into Q2 2024.

Gain Therapeutics (GANX) is set to participate in a virtual panel on March 29, 2023, at 12:00 pm ET, discussing advances in AI-enabled computational biology and drug discovery. The panel will feature Chief Technology Officer Xavier Barril and notable experts including Brandon Allgood and Jason Paragas, moderated by Hartaj Singh of Oppenheimer & Co. The discussion will cover topics such as precision medicine, the integration of machine learning in drug discovery, and innovative approaches to identifying allosteric binding sites using their proprietary SEE-Tx™ platform. Attendees can register for the live event and access a replay on Gain Therapeutics' website.

Gain Therapeutics (Nasdaq: GANX) has received a grant totaling €1.2 million from Eurostars and Innosuisse to develop small molecule regulators for Alpha-1 Antitrypsin (AAT) Deficiency. This rare genetic disorder can result in serious lung and liver diseases. The grant will fund collaborative research involving the Institute for Research in Biomedicine, Newcells Biotech, and the University of Helsinki. Gain’s proprietary platform, SEE-Tx, aims to identify allosteric sites and enhance therapeutic strategies for metabolic diseases. This recognition marks a significant validation of Gain’s innovative approach in addressing rare diseases.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that its CEO, Matthias Alder, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 8:40 AM ET. The conference will be conducted online, and a live webcast of the presentation can be accessed through the Company’s website. Gain Therapeutics specializes in drug discovery using a proprietary computational platform to identify novel allosteric binding sites for small molecule treatments. Their pipeline includes programs targeting neurodegenerative diseases and other disorders. The company has received funding support from various foundations and programs for its lead program in Parkinson’s disease.

Gain Therapeutics (Nasdaq: GANX) announced promising pre-clinical results for its GCase-targeting therapy for neuronopathic Gaucher disease at the 19th Annual WORLD Symposium. The study demonstrated that the compound GT-02329 restores β-glucocerebrosidase (GCase) activity, reduces toxic lipid accumulation, and improves neuromuscular function. CEO Matthias Alder highlighted the consistent preclinical data and affirmed plans to submit a dossier for Phase 1 clinical trials of their lead compound GT-02287 in mid-2023. This research addresses an unmet need as current enzyme replacement therapies do not penetrate the blood-brain barrier, leaving patients vulnerable.

Gain Therapeutics, Inc. (Nasdaq: GANX) has announced plans to present new preclinical data on its lead program targeting GBA1-related diseases during several upcoming scientific meetings. CEO Matthias Alder highlighted the significant data generated in the past year, demonstrating the drug candidate GT-02287’s mechanism and potential disease-modifying effects. Presentations will take place at notable conferences including the 19th Annual WORLDSymposium from February 22-26, 2023, in Orlando, FL, and AD/PD 23 from March 28-April 1, 2023, in Gothenburg, Sweden. Gain Therapeutics aims to enter clinical development later this year.